321 related articles for article (PubMed ID: 33887878)
41. Effect of rituximab combined with chemotherapy on the expression of serum exosome miR-451a in patients with diffuse large b-cell lymphoma.
Xiao XB; Gu Y; Sun DL; Ding LY; Yuan XG; Jiang HW; Wu ZX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1620-1625. PubMed ID: 30840285
[TBL] [Abstract][Full Text] [Related]
42. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Jauw YW; Zijlstra JM; de Jong D; Vugts DJ; Zweegman S; Hoekstra OS; van Dongen GA; Huisman MC
PLoS One; 2017; 12(1):e0169828. PubMed ID: 28060891
[TBL] [Abstract][Full Text] [Related]
43. Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma.
Zou L; Song G; Gu S; Kong L; Sun S; Yang L; Cho WC
Curr Cancer Drug Targets; 2019; 19(9):681-687. PubMed ID: 31142246
[TBL] [Abstract][Full Text] [Related]
44. Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway.
Zhou Z; Ma D; Li P; Wang P; Liu P; Wei D; Wang J; Qin Z; Fang Q; Wang J
Aging (Albany NY); 2020 Jun; 12(12):11364-11385. PubMed ID: 32570218
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.
Paik JH; Go H; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2013 Sep; 54(9):1934-41. PubMed ID: 23327292
[TBL] [Abstract][Full Text] [Related]
46. The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.
Liu Y; Gu JJ; Yang L; Tsai PC; Guo Y; Xue K; Xia Z; Liu X; Lv F; Cao J; Hong X; Mavis C; Hernandez-Ilizaliturri FJ; Zhang Q
Aging (Albany NY); 2020 Dec; 13(1):181-193. PubMed ID: 33288735
[TBL] [Abstract][Full Text] [Related]
47. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
48. MORTALIN-Ca
Sun Q; Ye Y; Gui A; Sun X; Xie S; Zhan Y; Chen R; Yan Y; Gu J; Qiu S; Liu W; Zuo J; Zhang Q; Yang L
Cancer Lett; 2022 Jul; 537():215678. PubMed ID: 35447282
[TBL] [Abstract][Full Text] [Related]
49. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
Tokunaga T; Tomita A; Sugimoto K; Shimada K; Iriyama C; Hirose T; Shirahata-Adachi M; Suzuki Y; Mizuno H; Kiyoi H; Asano N; Nakamura S; Kinoshita T; Naoe T
Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
51. Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
Jing XM; Yu JR; Luo YK; Zhang SC; Liu JF; Li L; Wu P; Zhang ZH
Leuk Res; 2017 Sep; 60():89-93. PubMed ID: 28772206
[TBL] [Abstract][Full Text] [Related]
52. Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B-cell lymphoma in the rituximab era.
Guan Q; Hong Y; Hu G; Zhou Q; Li L; Qian Z; Zhou S; Ren X; Qiu L; Wang X; Zhang H
Hematol Oncol; 2021 Oct; 39(4):490-497. PubMed ID: 33908077
[TBL] [Abstract][Full Text] [Related]
53. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
[TBL] [Abstract][Full Text] [Related]
54. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
55. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
56. MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8
Xu Y; Liu Z; Lv L; Li P; Xiu B; Qian W; Liang A
J Exp Clin Cancer Res; 2020 Nov; 39(1):238. PubMed ID: 33168024
[TBL] [Abstract][Full Text] [Related]
57. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML
Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of exosomal miR-155, let-7g and let-7i levels as a potential noninvasive biomarker among refractory/relapsed patients, responsive patients and patients receiving R-CHOP.
Zare N; Haghjooy Javanmard S; Mehrzad V; Eskandari N; Kefayat A
Leuk Lymphoma; 2019 Aug; 60(8):1877-1889. PubMed ID: 30714442
[TBL] [Abstract][Full Text] [Related]
59. MicroRNA-19b-3p regulates nasopharyngeal carcinoma radiosensitivity by targeting TNFAIP3/NF-κB axis.
Huang T; Yin L; Wu J; Gu JJ; Wu JZ; Chen D; Yu HL; Ding K; Zhang N; Du MY; Qian LX; Lu ZW; He X
J Exp Clin Cancer Res; 2016 Dec; 35(1):188. PubMed ID: 27919278
[TBL] [Abstract][Full Text] [Related]
60. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]